Vial sharing for bevacizumab that would otherwise have been discarded yielded a 97.88% reduction in the total cost of a single year of intravitreal injections, as well as a 96.54% increase in the number of injections performed.
The anti—vascular endothelial growth factor (anti-VEFG) therapy bevacizumab (Avastin) is increasingly used off-label for the treatment of retinal disorders, especially in regions where the high cost of other anti-VEFG therapies, like ranibizumab or aflibercept, is of special concern.
Given that bevacizumab is available at a lower cost than these other therapies—and that biosimilar bevacizumab is becoming commercially available at an even lower list price in some territories—the question of how to optimize this agent’s use in ophthalmology is of particular interest for health systems in search of cost savings.
One recent study from Brazil described the way in which vial sharing and pharmacist-led repackaging of bevacizumab used in oncology brought down costs for a public hospital that treats patients with retinal diseases.
The paper’s authors obtained patient information from medical records between 2015 and 2017, and compared the medications used, the costs of the medications, and cost of medicines in the case of vial sharing for bevacizumab, which was implemented by the hospital in 2016. In the vial-sharing procedure, bevacizumab that is left over from treating patients with cancer is removed from its original packaging, divided into smaller doses, and repackaged in a manner that preserves quality and includes identifying information for use in the ophthalmology clinic.
In the first year of the study, 550 intravitreal injections were performed: 192 of these injections were of bevacizumab (at a total cost of BRL$248,033.28, or US$64,016.84), 347 were of ranibizumab BRL$755,321.84, US$194,946.92), and 11 were of aflibercept (BRL$32,701.13, US$8440.09).
In the second year, 1081 doses were performed using bevacizumab obtained through vial sharing, with an isolated cost of BRL$17,455.98, (US$4514.28). When costs for the cleanroom where the drug was repackaged and costs for personnel were included, the total cost of vial sharing was BRL$21,942.49 (US$5663.30).
Vial sharing for bevacizumab that would otherwise have been discarded yielded a 97.88% reduction in the total cost of a single year of intravitreal injections, as well as a 96.54% increase in the number of injections performed.
The authors of the study note that high-cost medication wastage is not only a problem for health systems like that of Brazil; in the United States, they point out, bevacizumab waste was estimated to be 9% in 2016.
Given the results of this study, write the authors, further research should be encouraged to evaluate the effects of repackaging high-cost drugs as a way to more effectively use healthcare resources.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.